How has NewAmsterdam Pharma Company's non-cash interest expense changed year-over-year?

NewAmsterdam Pharma Company's non-cash interest expense increased by 101.9% year-over-year, from -$513K to $10K.

NewAmsterdam Pharma Company NAMS Non-cash interest expense

Non-cash interest expense at other companies

Laureate Education, Inc.LAUR

$593K+56.1%

Hycroft Mining Holding CorporationHYMC

$0-100%

Navan, Inc. NAVN

$447K-95.5%

Rhythm Pharmaceuticals, Inc.RYTM

$4.58M-15.4%

TransDigm GroupTDG

$12M+20.0%

Sarepta Therapeutics, Inc.SRPT

$9.61M+667%

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's non-cash interest expense?: NewAmsterdam Pharma Company (NAMS) reported non-cash interest expense of $10K in Q1 2026.
How has NewAmsterdam Pharma Company's non-cash interest expense changed year-over-year?: NewAmsterdam Pharma Company's non-cash interest expense increased by 101.9% year-over-year, from -$513K to $10K.